Investment surge fuels MimiX Biotherapeutics' advancements in human tissue regeneration

MimiX Biotherapeutics, a pioneering biomedical company, announces a substantial investment from strategic MedTech industry experts in Asia and Europe, solidifying its commitment to realizing the innovative potential of FastSkin®, a novel treatment technique for chronic and acute wound management. The company aims to introduce its wound care product into the US market by the second half of 2024.

The strategic investors are supporting MimiX's vision to transform the lives of millions of patients suffering from chronic wounds. The investment will accelerate the development and commercialization of FastSkin®, a revolutionary treatment that has the potential to significantly improve patient outcomes and reduce healthcare costs.

"We are thrilled to have the support of Heraeus Group and Asia Jetway, as we work to bring our innovative wound treatment to market," said Marc Thurner, CEO of MimiX. "Their expertise and resources will be invaluable to accelerate go-to-market and internationalization plans.”

The successful completion of the funding marks a significant milestone for MimiX, as it moves closer to achieving its mission of improving chronic wound management. With the support of its investors and stakeholders, the company is well-positioned to bring FastSkin® to market and make a lasting impact on the lives of patients around the world.

MimiX Biotherapeutics participated in Venture Leaders Medtech 2023 and won Venture Kick Stage 2 in 2020.

"The Venture Leaders program is a great networking opportunity! It was a door-opener for me to industrial and clinical contacts in the US and allowed me to create a strong connection with fellow CEOs in Switzerland. The exchange with other CEOs is as important for me as creating business contacts with future clients and partners," said Marc.


Source: MimiX press release